Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 11:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Contrast enhanced CT Clear all
Not yet recruiting Not applicable Interventional

LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol A

NCT07685028
View directory record Official record
Conditions
Family History of Lung Cancer
Interventions
CT scan, Sybil
Diagnostic Test · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 20, 2026, 11:52 PM EDT
Completed Not applicable Interventional

Imaging the Patterns of Breast Cancer Early Metastases

NCT02706964
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron emission tomography/x-ray computed tomography, Magnetic resonance imaging, x-ray computed tomography (CT)
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 110 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Gainesville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 20, 2026, 11:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison

NCT00626366
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
Sinus CT Scan, Omnipaque 240 Contrast Solution, Omnipaque 240 mg I/mL
Radiation · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 20, 2026, 11:52 PM EDT
Active, not recruiting Phase 3 Interventional

Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble

NCT01224288
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Perfusion CT scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 20, 2026, 11:52 PM EDT
Completed Phase 2 Interventional

Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect

NCT02598596
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, Azathioprine
Biological · Drug
Lead sponsor
Ampel BioSolutions, LLC
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
Birmingham, Alabama • Huntsville, Alabama • Wheaton, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 20, 2026, 11:52 PM EDT
Completed Not applicable Interventional

Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection

NCT01575951
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
MRI-DCE
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 20, 2026, 11:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Renal Artery Contrast-Free Trial

NCT01576835
View directory record Official record
Conditions
Renal Artery Stenosis, Kidney Diseases, Hypertension
Interventions
Not listed
Lead sponsor
Central Coast Cardiovascular Research
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Salinas, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 20, 2026, 11:52 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Breast CT

NCT00584233
View directory record Official record
Conditions
Breast Cancer
Interventions
computed tomography, MRI
Device
Lead sponsor
University of California, Davis
Other
Eligibility
35 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Sep 20, 2026, 11:52 PM EDT
Not listed Not applicable Interventional

Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy

NCT01082224
View directory record Official record
Conditions
Liver Cancer
Interventions
iodinated contrast dye, motexafin gadolinium, Eovist-enhanced MRI
Drug · Other
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
9
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 20, 2026, 11:52 PM EDT
Completed Phase 2 Interventional

18-F Sodium Fluoride (18F-NaF) PET for the Assessment of Bioprosthetic Aortic Valve Durability and Outcomes

NCT03095313
View directory record Official record
Conditions
Aortic Stenosis
Interventions
18F-NaF
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 20, 2026, 11:52 PM EDT
Recruiting Early Phase 1 Interventional

Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy

NCT07436364
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Definity, Contrast-Enhanced Ultrasound
Drug · Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 20, 2026, 11:52 PM EDT
Active, not recruiting No phase listed Observational

Assessing How Normal Variations in CT Scanning Affects Its Interpretation

NCT03038568
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
CT scan
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 20, 2026, 11:52 PM EDT
Completed Phase 2 Interventional Results available

Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation

NCT02440334
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Optison
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 20, 2026, 11:52 PM EDT
Terminated Not applicable Interventional Results available

Positron Emission Tomography/Magnetic Resonance Imaging in Patients

NCT01557881
View directory record Official record
Conditions
Colon Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Malignant Neoplasm, Melanoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
magnetic resonance imaging with positron emission tomography scanning
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 20, 2026, 11:52 PM EDT
Terminated Not applicable Interventional Results available

Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery

NCT02881554
View directory record Official record
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer, Vascular Thrombosis
Interventions
Computed Tomography, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 20, 2026, 11:52 PM EDT
Recruiting Not applicable Interventional

Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)

NCT07002450
View directory record Official record
Conditions
Atrial Fibrillation (AF), Atrial Flutter
Interventions
Cardiac computed tomography angiography, Standard of care management
Diagnostic Test · Other
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 20, 2026, 11:52 PM EDT
Recruiting Not applicable Interventional

Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

NCT04442724
View directory record Official record
Conditions
Bladder Cancer, Urinary Bladder Neoplasm, Urologic Neoplasms, Neoplasms, Urinary Bladder Diseases
Interventions
Fiducial marker placement, Multiparametric MRI (mpMRI)
Procedure · Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 20, 2026, 11:52 PM EDT
Completed No phase listed Observational

Diffusion-Weighted MRI for Liver Metastasis

NCT02781935
View directory record Official record
Conditions
Colorectal Cancer, Colon Cancer Liver Metastasis, Malignant Neoplasm of Rectum Metastatic to Liver
Interventions
DW-MRI
Procedure
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 20, 2026, 11:52 PM EDT
Recruiting Not applicable Interventional

A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer

NCT07324096
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography with Contrast, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 20, 2026, 11:52 PM EDT
Recruiting Phase 1 Interventional

GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas

NCT07417488
View directory record Official record
Conditions
Colorectal Cancer, Small Bowel Adenocarcinoma
Interventions
Ad5.F35-hGUCY2C-PADRE vaccine, Lm-GUCY2C vaccine, CT Scan
Biological · Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 20, 2026, 11:52 PM EDT
Active, not recruiting Not applicable Interventional

An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma

NCT04837833
View directory record Official record
Conditions
Pancreas Cancer, Gastrointestinal Adenocarcinoma
Interventions
ultrasound
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 20, 2026, 11:52 PM EDT
Terminated Early Phase 1 Interventional

Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE

NCT04150874
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
Lumason®
Diagnostic Test
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 20, 2026, 11:52 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

NCT04739800
View directory record Official record
Conditions
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Mucinous Adenocarcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Refractory Fallopian Tube Clear Cell Adenocarcinoma, Refractory Fallopian Tube Endometrioid Adenocarcinoma, Refractory Fallopian Tube High Grade Serous Adenocarcinoma, Refractory Fallopian Tube Mucinous Adenocarcinoma, Refractory Fallopian Tube Transitional Cell Carcinoma, Refractory Fallopian Tube Undifferentiated Carcinoma, Refractory Low Grade Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian Endometrioid Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Refractory Ovarian Low Grade Serous Adenocarcinoma, Refractory Ovarian Mucinous Adenocarcinoma, Refractory Ovarian Seromucinous Carcinoma, Refractory Ovarian Transitional Cell Carcinoma, Refractory Ovarian Undifferentiated Carcinoma, Refractory Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Primary Peritoneal Endometrioid Adenocarcinoma, Refractory Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Transitional Cell Carcinoma, Refractory Primary Peritoneal Undifferentiated Carcinoma
Interventions
Biospecimen Collection, Cediranib Maleate, Computed Tomography, Computed Tomography with Contrast, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
384
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 20, 2026, 11:52 PM EDT
Terminated No phase listed Observational

Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis

NCT03929822
View directory record Official record
Conditions
Breast Screening
Interventions
Contrast-Enhanced Spectral Mammography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Sep 20, 2026, 11:52 PM EDT